Dianthus CFO Savitz sells 31,249 shares in plan

Rhea-AI Filing Summary

Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options for 31,249 shares of common stock at $21.77 per share on July 9, 2026, then sold the 31,249 shares in three open-market transactions at weighted average prices of $100.22, $101.24 and $101.97 pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Following these sales, he reported no directly held common shares and reported holdings of 68,751 stock options from an award that vests in equal monthly installments over four years after May 1, 2024.

Filing Explained

The July 9 transactions left the officer with no direct common stock and 68,751 remaining options under a plan adopted December 30, 2025.

The July 13, 2026 Form 4 reports that Ryan Savitz, Dianthus’s EVP, CFO and CBO, exercised 31,249 stock options and acquired the underlying common stock on July 9, 2026.

The filing reports three same-day sales of 10,354, 15,329, and 5,566 common shares, leaving 0 direct common shares and 68,751 options.

Under the Form 4 code definitions, M denotes an option or derivative exercise and S denotes an open-market sale.

The filing states that the reported transactions were made under a Rule 10b5-1 plan adopted on December 30, 2025; that disclosure identifies the plan’s adoption date, not the reasons for individual trades.

The sale prices are reported as weighted averages of $100.22, $101.24, and $101.97, with disclosed execution ranges of $99.75–$100.74, $100.78–$101.75, and $101.95–$102.15, respectively.

The filing says the remaining stock-option award vests in equal monthly installments over four years after May 1, 2024, subject to continued service, and lists May 22, 2034 as its expiration date.

Insider Trade Summary 10b5-1

Exercise and Sale: 31,249 shares ($2.48M approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Savitz Ryan

Role EVP, CFO & CBO

Sold 31,249 shs ($3.16M)

Approx. gross sale proceeds $3.16M

Approx. exercise cost $680K

Approx. pre-tax spread $2.48M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F5	31,249	$0.00	$0.00
Exercise	Common Stock F1	31,249	$21.77	$680K
Sale	Common Stock F1, F2	10,354	$100.22	$1.04M
Sale	Common Stock F1, F3	15,329	$101.24	$1.55M
Sale	Common Stock F1, F4	5,566	$101.97	$568K

Holdings After Transaction: Stock Option (Right to Buy) — 68,751 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (5)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.75 to $100.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.95 to $102.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 05:00 PM Accepted by SEC EDGAR 07/13/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savitz Ryan

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CFO & CBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M(1)		31,249	A	$21.77	31,249	D
Common Stock	07/09/2026		S(1)		10,354	D	$100.22(2)	20,895	D
Common Stock	07/09/2026		S(1)		15,329	D	$101.24(3)	5,566	D
Common Stock	07/09/2026		S(1)		5,566	D	$101.97(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.77	07/09/2026		M(1)			31,249	(5)	05/22/2034	Common Stock	31,249	$0	68,751	D

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.75 to $100.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.95 to $102.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Ryan Savitz	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)